NASDAQ:OLMA

Olema Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy OLMA

*Your capital is at risk

$11.85

-0.0600 (-0.504%)

At Close: Jul 13, 2026

Olema Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -49.08. In total, the insiders bought 3.97M and sold 1.26M OLMA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-49.08
● Buy	3.97M shares
● Sell	1.26M shares
64% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Jun 18, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -49.08. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Graham G. Walmsley Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (Right to buy) A-Award	Bvf Partners L P/il See Explanation Of Responses	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Harmon Cyrus Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Butitta Cynthia M Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Garland J. Scott Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Hrustanovic Gorjan Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Clark Ian T Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Larson Yi Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Horning Sandra Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Raman Prakash Director	Director	29 500 Value: $280.5K
Jun 18, 2026 Buy	Stock Option (right to buy) A-Award	Rappaport Andrew Director	Director	29 500 Value: $280.5K
Apr 28, 2026 Buy	Stock Option (Right to Buy) A-Award	Raman Prakash Director	Director	2 911 Value: $42.5K
Apr 28, 2026 Buy	Stock Option (Right to Buy) A-Award	Raman Prakash Director	Director	24 150 Value: $352.3K
Apr 28, 2026 Buy	Common Stock J-Other	Raman Prakash Insider	Other	0 Value: $0
Mar 04, 2026 Sell	Comon Stock S-Sale	Mitchell Shawnte Chief Legal Officer	Officer	233 Value: $6K
Mar 04, 2026 Sell	Common Stock S-Sale	Mitchell Shawnte Chief Legal Officer	Officer	24 767 Value: $600.6K
Mar 04, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Mitchell Shawnte Chief Legal Officer	Officer	25 000 Value: $109.3K
Mar 04, 2026 Buy	Common Stock M-Exempt	Mitchell Shawnte Chief Legal Officer	Officer	25 000 Value: $109.3K
Mar 03, 2026 Sell	Common Stock S-Sale	Mitchell Shawnte Chief Legal Officer	Officer	15 000 Value: $345.2K
Mar 03, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Mitchell Shawnte Chief Legal Officer	Officer	15 000 Value: $65.6K
Mar 03, 2026 Buy	Common Stock M-Exempt	Mitchell Shawnte Chief Legal Officer	Officer	15 000 Value: $65.6K
Feb 02, 2026 Buy	Common Stock A-Award	Austin Sasha Lu Vp Of Finance And Controller	Officer	11 700 Value: $300.1K
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Austin Sasha Lu Vp Of Finance And Controller	Officer	29 250 Value: $750.3K
Feb 02, 2026 Buy	Performance Stock Options (Right to Buy) A-Award	Bohen Sean President And CEO	CEO / President	275 000 Value: $7.05M
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Zojwalla Naseem Chief Medical Officer	Officer	250 000 Value: $6.41M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OLEMA PHARMACEUTICALS INC

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negativ...

Read Full Profile Here